Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pathophysiol. Nov 15, 2015; 6(4): 210-218
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.210
Risk factors for osteoporosis in inflammatory bowel disease patients
Carla Andrade Lima, Andre Castro Lyra, Raquel Rocha, Genoile Oliveira Santana
Carla Andrade Lima, Pos-graduation program in medicine and health, Federal University of Bahia, Salvador, Bahia 40110-060, Brazil
Andre Castro Lyra, Genoile Oliveira Santana, Department of Gastroenterology, Federal University of Bahia, Salvador, Bahia 40110-060, Brazil
Raquel Rocha, Department of Sciences of Nutrition, School of Nutrition, Federal University of Bahia, Salvador, Bahia 40110-060, Brazil
Author contributions: Lima CA performed most of the writing and prepared the table; Lyra AC coordinated the writing of the paper; Rocha R coordinated the writing of the paper; Santana GO designed the outline and coordinated the writing of the paper.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior authors or coauthors who contributed their efforts to this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Raquel Rocha, DMSc, Department of Science of Nutrition, School of Nutrition, Federal University of Bahia, Salvador, Araujo Pinho Avenue, number 32, Bahia 40110-060, Brazil.
Telephone: +55-71-99749964
Received: April 18, 2015
Peer-review started: April 18, 2015
First decision: June 18, 2015
Revised: August 22, 2015
Accepted: September 16, 2015
Article in press: September 18, 2015
Published online: November 15, 2015


Inflammatory bowel disease (IBD) patients exhibit higher risk for bone loss than the general population. The chronic inflammation causes a reduction in bone mineral density (BMD), which leads to osteopenia and osteoporosis. This article reviewed each risk factor for osteoporosis in IBD patients. Inflammation is one of the factors that contribute to osteoporosis in IBD patients, and the main system that is involved in bone loss is likely RANK/RANKL/osteoprotegerin. Smoking is a risk factor for bone loss and fractures, and many mechanisms have been proposed to explain this loss. Body composition also interferes in bone metabolism and increasing muscle mass may positively affect BMD. IBD patients frequently use corticosteroids, which stimulates osteoclastogenesis. IBD patients are also associated with vitamin D deficiency, which contributes to bone loss. However, infliximab therapy is associated with improvements in bone metabolism, but it is not clear whether the effects are because of inflammation improvement or infliximab use. Ulcerative colitis patients with proctocolectomy and ileal pouches and Crohn’s disease patients with ostomy are also at risk for bone loss, and these patients should be closely monitored.

Key Words: Bone mineral density, Crohn’s disease, Osteoporosis, Ulcerative colitis, Inflammatory bowel disease, Risk factors

Core tip: Inflammatory bowel disease (IBD) is associated with bone loss. Some factors reduce bone mineral density and lead to osteopenia and osteoporosis. The major complication in osteoporosis is the increased risk of fracture, which may impact quality of life. This article reviews each risk factor for osteoporosis in IBD patients, like chronic inflammation, smoking, body composition, corticosteroid use, vitamin D deficiency, surgery, and the effect of infliximab therapy.

Citation: Lima CA, Lyra AC, Rocha R, Santana GO. Risk factors for osteoporosis in inflammatory bowel disease patients. World J Gastrointest Pathophysiol 2015; 6(4): 210-218

Inflammatory bowel disease (IBD), which is primarily comprised of ulcerative colitis (UC) and Crohn’s disease (CD), is associated with various systemic complications, such as extra-intestinal manifestations (EIMs)[1]. These complications are found in approximately 40% of IBD patients. The most widely known EIMs are skin lesions (erythema nodosum and pyoderma gangrenosum), articular manifestations and liver diseases (primary sclerosing cholangitis and primary biliary cirrhosis)[2,3].

IBD patients exhibit a higher risk for bone loss than the general population. Chronic inflammation causes a reduction in bone mineral density (BMD), which leads to osteopenia and osteoporosis. Cross-sectional studies reported a highly variable prevalence of low BMD in IBD patients. The prevalence of osteopenia and osteoporosis varies significantly depending on the study population, location, and design, but it ranges from 22%-77% and 17%-41%, respectively[4].

The incidence of inflammatory bowel disease seems stable in Western countries, but this disease has become more prevalent in Eastern countries, including Asia and Eastern Europe[5]. Extra-intestinal manifestations are also present in IBD patients in Eastern countries. Some studies demonstrated that these patients are at risk for bone loss and osteoporosis[6].

Dual-energy X-ray absorptiometry (DXA) is the current gold standard technique for the measurement of bone mass. Measurements are generally obtained at the femoral neck and lumbar spine. DXA results are typically expressed as the number of standard deviations (SD) above or below the expected mean for individuals of the same age, ethnicity and gender (Z score) or the mean of peak bone mass in young adults (T score)[7-9]. The World Health Organization reported formulated diagnostic ranges for osteoporosis based on T scores. Osteoporosis and osteopenia are defined by a T score below -2.5, and between -1 and -2.5, respectively. These recommendations were derived from postmenopausal Caucasian females. Therefore, caution must be exercised when extrapolating these data to other groups[9,10]. The current guidelines recommend DXA screening in IBD patients with one or more of the following risk factors: History of vertebral fractures, postmenopausal, male > 50 years of age, chronic corticosteroid therapy, or hypogonadism[9-11].

The major complication of bone loss and osteoporosis is the increased risk of fracture, especially non-traumatic fractures[12,13]. Bernstein et al[14] demonstrated that the incidence of fracture in persons with IBD is 40% greater than the general population. Other authors also reported similar findings[15-17]. Whether differences between IBD type (CD or UC) and BMD exist are not known. A cross-sectional population based study by Jahnsen et al[18] found that CD patients exhibited significantly reduced BMD compared to UC patients and healthy controls. A cohort of 3141 IBD patients in Taiwan also demonstrated a higher risk of osteoporosis in CD patients than UC patients[6]. However, these results are not consistent with other reports.

Whether gender interferes with BMD in IBD patients is not known. Ardizzone et al[19] demonstrated that spine and femur BMD Z and T scores were significantly lower in men than women UC patients, but this difference was not demonstrated in CD patients. A case control cross-sectional study of 113 CD patients found that female patients exhibited significantly decreased BMD of the femoral neck and the trochanteric region, but BMD was not significantly different from healthy controls in men[20].

Other risk factors associated to IBD or the general population are also related to the loss of bone mass with older age, postmenopausal status, smoking, malnutrition, physical inactivity, corticosteroid use for more than three months and vitamin D deficiency[21].

This review describes the specific risk factors for osteoporosis in IBD patients.


Many factors exert important effects on bone metabolism, but there is increasing evidence that inflammation per se contributes to osteoporosis in IBD. Some studies in patients with newly diagnosed IBD demonstrated a reduction of BMD, even without the use of medications, such as corticosteroids[22,23].

Several chronic inflammatory disorders are associated with osteoporosis and an increased number of fractures. Inflammation is characterized by the production of cytokines, which is associated with increased bone resorption and reduced bone formation. The main system involved in the development of osteoporosis in IBD and other inflammatory diseases is likely the RANK/RANKL/osteoprotegerin[24].

The receptor activator of nuclear factor-B (RANK) is a transmembrane protein that is expressed on the surface of cells of hematopoietic origin that belongs to the TNF receptor family. RANK is the primary cytokine receptor in the development of osteoclastogenesis[25-28]. The ligand for RANK receptor (RANKL) is expressed on the surface of osteoblasts, mesenchymal cells and other cells, such as T and B lymphocytes. The binding of RANKL to RANK induces the differentiation of osteoclast precursors. RANKL also increases the resorptive activity of osteoclasts and prolongs their survival by suppressing apoptosis[25-28].

Osteoblasts produce osteoprotegerin (OPG) as a control to maintain balance. OPG is a decoy receptor molecule that naturally binds RANKL to inhibit osteoclast activation and protect against bone loss[25-28]. Chronic inflammatory states mediated by T cell-produced cytokines affect osteoblasts and osteoclasts. Activated T cells produce RANKL and its soluble form, which directly triggers bone loss via the induction and activation of osteoclasts by RANK[29].

Several pro-inflammatory cytokines are involved in the activation of osteoclasts, such as interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α), IL-6, IL-11, IL-15 and IL-17[30]. IL-6 plays an important role in the mediation of inflammatory osteoporosis, and it may also be involved in the pathways that lead to osteoporosis but are not elicited by inflammation[31].

Turk et al[32] demonstrated that patients with newly diagnosed and untreated CD exhibited elevated proinflammatory cytokines levels (IL-6, TNF-α, and IL-1) and increased free RANKL and OPG activity. These authors also observed a positive correlation between TNF-α and sRANK.

Disease activity interferes with bone metabolism. Some studies demonstrated that patients with disease in remission exhibit an increase in BMD. Reffitt et al[33] analyzed 137 IBD patients and demonstrated that patients with longer disease remission exhibited higher BMD.


Smoking has been recognized as a risk factor for bone loss and fractures for many years. Several mechanisms were proposed to explain the differences in BMD between smokers and non-smokers. However, the pathophysiological mechanisms underlying osteoporosis in cigarette smokers have not been fully explored[34,35].

Some studies demonstrated that the dose and duration of smoking may influence the effect of smoking on bone[35,36]. Smoking seems related to a vitamin D deficiency, and one possible explanation is that smoking alters the hepatic metabolism of vitamin D by influencing 25 hydroxylase in the liver, which lowers serum 25-hydroxyvitamin D[34,35]. There is also evidence that smoking alters gastrointestinal calcium absorption. Smokers lead an unhealthy lifestyle that includes low calcium/vitamin D intake, lack of exercise and alcohol ingestion, which affects bone health[34,35].

Whether smoking is associated with estradiol levels is controversial, but some studies demonstrated that smoking alters estrogen production and metabolism. There are some possible mechanisms. Nicotine may reduce estrogen production, and smoking enhances the hepatic metabolism of estradiol. Smokers exhibit higher serum sex-hormone binding globulin levels, which reduces free estradiol concentrations[34,35].

Few studies investigated the relationship between smoking and the RANK-RANKL-OPG system. Some reports demonstrated that smokers exhibit lower OPG levels without a difference in RANKL levels[36]. A cross-sectional study of 126 UC and 39 CD Iranian IBD patients demonstrated that femoral neck T scores were predicted by age, body mass index (BMI), smoking, and corticosteroid use. However, the association between smoking and BMD was not observed in the lumbar spine in this study[37]. Silvennoinen et al[38] evaluated the effect of smoking on BMD in 152 IBD patients (67 UC, 78 CD, 7 indeterminate colitis) and 73 controls and found that female IBD patients who currently smoked or with a previous history of smoking exhibited lower Z scores for the lumbar spine and femoral neck than female patients who had never smoked.

Smoking is also associated with relapses and disease activity (especially CD) and the need for steroids, which also negatively interferes with bone metabolism. The suspension of smoking is associated with more flare-ups in UC patients. However, smoking cessation should be encouraged in all IBD patients because it reduces other complications, such as cardiovascular disease, lung cancer and changes in bone health[39].


Low BMI is a well-documented risk factor for low BMD and fracture[40]. Azzopardi et al[41] analyzed the risk factors for osteoporosis in 83 CD patients and found a significant association between BMI and BMD.

Many others studies also identified a positive association between BMD and BMI[42-44]. Atreja et al[45] also considered BMI a strong risk factor for altered bone metabolism and a way to identify osteoporotic patients who are missed by current guidelines. Leslie et al[46] studied 388 IBD patients and found that greater weight, height, and body mass measurements positively correlated with bone density at all sites. Fat and lean tissues exhibited positive relationships with BMD in this study, but lean tissue exhibited a much stronger correlation than fat tissue, especially for the total hip.

Low BMI is a risk factor for fractures, but whether obesity is a protective factor is not clear because obesity increases the risk of some osteoporotic fractures[47,48]. Johansson et al[49] published a recent meta-analysis of the association of fracture risk and BMI in women and concluded that there is a slight increase in osteoporotic fracture risk with increasing BMI after adjustment for BMD. Therefore, body composition appears more important than BMI in bone metabolism.

Mechanical loading of the muscles that act on the bone produce an anabolic effect, which results in osteogenesis[50,51]. Many IBD patients have reduced muscle (lean mass) because of nutritional factors, a sedentary lifestyle or medications, and these factors may lead to a reduced bone mass that is secondary to the decrease in mechanical stimulation of the skeleton[52].

A Canadian study analyzed the bone mass (bone mineral content) and muscle mass (lean mass) of 65 CD patients. Multiple regression analysis demonstrated that only total lean mass was independently associated with lumbar bone mineral content (BMC), BMC in both hips and total BMC[52]. Lee et al[53] demonstrated a similar effect in a cohort of 61 CD patients. This study found that lean mass and muscle strength, but not fat mass, significantly correlated with regional and whole body BMD, but lean mass was the only independent predictor of hip BMD after multiple regression analysis. These authors concluded that maintaining or increasing muscle mass may positively affect BMD and prevent the development of osteopenia and osteoporosis.


Glucocorticoids (GCs) are frequently used in the treatment of inflammatory conditions, such as rheumatoid arthritis, systemic lupus erythematous, asthma and IBD. GC exposure is common in IBD patients, and over 50% of patients are exposed to systemic GCs within 5 years of diagnosis, and 20% have used at least 3 g of prednisone in any 1-year period[54].

Many studies consistently identified systemic GC use as a risk factor for osteoporosis and bone mineral loss in IBD patients[54,55]. Abraham et al[56] studied 166 IBD patients and demonstrated that the risk of osteoporosis was twice as high in patients who used corticosteroids [OR = 2.4 (1.5-3.4), P = 0.001].

Osteoporosis attributed to GC exposure is the most common etiology of drug-induced osteoporosis. Approximately 50% of patients receiving chronic GC therapy will develop osteopenia and fractures, and 17% of these patients will develop fractures within the first year of GC therapy[57].

Some risk factors for the development of fractures after steroid exposure were identified: Age older than 65 years, cumulative steroid dose (high GC dose and duration of treatment > 3 mo), positive family history of osteoporosis, low calcium intake, female sex, low bodyweight (BMI < 24 kg/m2) and low BMD[57,58].

The mechanism of this loss is not fully understood. GC exposure alters the balance between osteoclast and osteoblast activity in bone metabolism. One important mechanism for the effects of GC on bone is osteoblastic dysfunction. GC inhibits stem cell differentiation into osteoblasts and induces osteoblast apoptosis, which decreases the secretion of osteoid matrix and new bone formation[57,59].

GCs increase the expression of RANKL and decrease the expression of its soluble decoy receptor OPG in stromal and osteoblastic cells. These alterations caused a greater differentiation of precursors into osteoclasts, which increases their resorptive activity and enhances bone reabsorption. There is also evidence that GCs directly prolong the lifespan of mature osteoclasts[57,59,60]. The increase in RANKL is only transient. Therefore, the failure of bone formation, rather than increased bone resorption, is likely the main mechanism underlying glucocorticoid-associated bone loss[58].

GCs also exhibit a negative effect on sex hormones status because GCs reduce estrogen and testosterone production. This negative effect of oral GCs on gonadal function may increase bone resorption[52,54].

GCs reduce intestinal calcium absorption and inhibit calcium reabsorption in the kidney, which indirectly leads to a negative net calcium balance and stimulates an increase in parathyroid hormone. These changes further increase the number of osteoclasts and stimulate bone resorption[57,58].


The role of vitamin D in IBD was not investigated in recent years. This vitamin primarily increases serum calcium and phosphate levels and promotes bone mineralization.

Vitamin D is available in two forms: Vitamin D3 (cholecalciferol), which is produced in the skin by exposure to sun light and obtained from animal sources, and vitamin D2 (ergocalciferol), which is obtained from plant sources. Vitamin D is metabolized in the liver to 25-hydroxyvitamin D [25-(OH) D], which circulates in the blood plasma and is stored in fat tissue and muscles. Metabolites of vitamin D are transported bound to albumin binding protein or vitamin D. This protein regulates the effects of the metabolites in target organs[61].

A study of 49 healthy young men demonstrated that free and bioavailable 25-(OH) D positively correlated with BMD, which suggests a possible benefit of vitamin D supplementation during deficiencies[62].

Vitamin D exerts its biological effects through the vitamin D receptor[61]. Multiple tissues and immune cells express this receptor, and these cells contain the enzyme that converts vitamin D into its active metabolite. Therefore, vitamin D appears to influence the innate immune response by inhibiting the maturation of dendritic cells and IL-12 and the adaptive immune response by inhibiting the production of IFN-γ, IL-17 and IL-21[63,64].

Several studies demonstrated a high prevalence of vitamin D deficiency in IBD patients. Many factors are attributed to this deficiency, and some of these factors are common to the general population, such as low sun exposure, inadequate intake, inactivity and other factors related to inflammatory disease, such as terminal ileum resection and low absorption due to the inflammatory process[64]. Disease activity is also associated with low levels of vitamin D in CD and UC patients[65,66].

Vitamin D deficiency leads to reduced calcium and secondary hyperparathyroidism, which stimulates osteoclastogenesis, increases bone resorption, and results in osteopenia and osteoporosis[64].


Elevated TNF-α concentration may play a role in dysfunctional bone metabolism in IBD. TNF-α is a major factor in the inactivation of osteoclasts. This cytokine induces osteoclast differentiation, increases osteoclast bone resorption, and protects these cells against apoptosis, which sensitizes osteoblasts to apoptosis and diminishes bone formation[67].

Infliximab (IFX) is a monoclonal antibody that exhibits high affinity and specificity for TNF-α. Anti-TNF therapy is an important IBD treatment because it allows for remission induction, relapse prevention and a decrease in corticosteroid use[68]. Some studies demonstrated the benefits of IFX use on BMD (Table 1). However, the exact mechanism of action of this anti-TNF in bone metabolism is not clear.

Table 1 Infliximab effects on bone mineral density in Crohn’s disease.
Ref.Study design1Participants numberEndpointsResults
Miheller et al[69]Prospective29 CD patientsDetermine the effects of IFX on bone metabolism in CD patientsIFX improves bone metabolism in CD independently from the behavior of the disease
Abreu et al[70]Prospective38 CD patientsAssess the ability of IFX to increase bone formation measured by markers of bone turnover in active CD patientsTreatment with IFX was associated with increased markers of bone formation
Franchimont et al[71]Prospective71 CD patients, 68 controlsAssess the evolution of markers of bone turnover after IFX treatment for active CDIFX induces improvement in biochemical markers of bone turnover
Mauro et al[72]Retrospective15 CD patients, 30 controlsAssess whether treatment with IFX had a beneficial effect on lumbar bone massTreatment with IFX was associated with significant increases in lumbar bone area, BMC and BMD in CD patients
Pazianas et al[73]Retrospective61 CD patientsEvaluate the effects of IFX administration on BMD in CD patientsIFX may work in synergy with bisphosphonates to provide additional increases in BMD in CD patients

Miheller et al[69] investigated the effects of IFX on bone metabolism by measuring biochemical parameters in 29 CD patients and found that IFX increased osteocalcin levels (marker of bone formation) and reduced beta-Cross Laps levels (marker of bone resorption).

Abreu et al[70] observed increased bone alkaline phosphatase (bone formation marker) in 38 CD patients treated with IFX and no significant change in the dose of N-telopeptide of type I collagen (NTX-marker of bone resorption). Franchimont et al[71] also examined the evolution of biochemical markers of bone metabolism after the first treatment with IFX in 71 CD patients. The authors of this study detected a normalization of bone markers after 8 wk of IFX treatment, with a median increase in formation markers of 14%-51%, according to the marker, and an approximately 10% reduction in bone resorption[71].

A retrospective study by Mauro et al[72] in 15 CD patients treated with IFX demonstrated significant increases in BMC and BMD in the lumbar spine compared to the control group.

The benefit of using IFX in BMD was also demonstrated with its associated use with bisphosphonates, as noted by Pazianas et al[73] in a retrospective cohort. They studied 61 CD patients, and patients who used bisphosphonates plus IFX experienced a greater increase in BMD than patients who used only bisphosphonate (6.7%/year vs 4.46%/year, P < 0.05).

The mechanism of action of IFX on bone metabolism is not well established, but its benefits in BMD may occur via the alteration of bone markers, the reduction of GC utilization and the induction of clinical and endoscopic remission.

Adalimumab is a human monoclonal IgG1 antibody that is specific for human TNF. It is also used in the treatment of IBD and other inflammatory diseases, such as rheumatoid arthritis and spondyloarthritis[74]. Studies demonstrated benefits in BMD in some patients using this therapy. Durnez et al[75] studied 59 patients with spondylo arthropathy treated with anti-TNF (infliximab, adalimumab or etarnecept) during a follow up of 6.5 years and found an increase in BMD of 11.8% in the lumbar spine and 3.6% in the trochanter.

Wijbrandts et al[76] conducted a prospective, open-label study of 50 rheumatoid arthritis patients. They analyzed the mineral density of the lumbar spine and femoral neck before and 1 year after adalimumab treatment. The authors observed no significant changes in BMD in lumbar spine (0.3%) or femoral neck (0.3%) and concluded that therapy with this anti-TNF does not increase BMD, but it can stop bone loss.

Another study by Krieckaert et al[77] evaluated the effect of long-term adalimumab use on BMD of the lumbar spine, hip and hands of rheumatoid arthritis patients. A total of 184 patients were studied, and hip and lumbar spine BMD remained stable after 1 year of treatment, but BMD in the hands decreased significantly by 1.41%. The mean BMD change per year was -0.58% and 0.07% for hip and lumbar spine, respectively, after a mean follow-up of 4.0 years (overall P value of hip was < 0.0001 and spine was 0.67). The authors considered that the BMD changes were associated to disease activity.

However, there are currently no published data investigating the effect of adalimumab on bone metabolism in IBD patients. There are also no data with certolizumab pegol.


Proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the procedure of choice for the treatment of most patients with refractory UC, UC with dysplasia and familial adenomatous polyposis[78-80]. Some studies demonstrated an increase in long-term BMD after total colectomy with IPAA[79]. This surgery may improve BMD in UC patients, possibly due to the discontinuation of corticosteroids, improvement in nutritional status and a decreased production of cytokines by the diseased colon[78,79].

However, it is unclear whether total colectomy with ileal pouch provides benefits or detriments to BMD. In a study of 327 UC patients who underwent this surgery, 32% had low BMD 4 years after surgery, which suggests that bone loss continues after colectomy[78].

Possible risk factors and mechanisms of bone loss are considered. An ileal pouch changes the anatomy and function of the small intestine by reducing the absorption of bile salts, which contributes to the reduced absorption of vitamin D. The stasis of stool in the ileum in UC patients with IPAA promotes bacterial overgrowth, which causes deconjugation of bile salts and leads to the malabsorption of vitamin D[79]. Another mechanism is inflammation of the ileal pouch, which increases inflammatory cytokines levels, such as IL-1, IL-6 and TNF-α, and stimulates osteoclast activity and promotes bone loss[79].

Navaneethan et al[81] also found a lower BMD in UC patients undergoing total proctocolectomy and ileal pouch compared to the control group (31.1% vs 15.1%, P < 0.001). They also found that BMD was already low before surgery in 13 patients, and 7 (53.8%) of these patients exhibited an increase in BMD after surgery. Some studies demonstrated a higher incidence of fractures in UC patients with IPAA, ranging from 7%-15%[78,81].

IBD patients, particularly CD, are at increased risk of surgery based on disease severity and duration. The most common surgery for CD patients involves removal of the terminal ileum, which is associated to a vitamin D deficiency and the consequent secondary hyperparathyroidism, which promotes bone mass reduction. However, the relationship of these factors with osteoporosis in CD is not well defined[54].

Gupta et al[82] analyzed 126 patients with ostomy, and 95% of these patients had CD and ileostomy. This study also demonstrated a high frequency of fractures (9.5%) in CD patients after ostomy, with significantly higher rates in patients with low BMD. IBD patients with ostomy and low BMD also exhibited low BMI. Fractures were also five times more frequent in IBD patients with ostomy and low BMD.

IBD patients with ostomy are at higher risk for bone loss, and these patients should be monitored closely, especially patients with risk factors, such as low BMI and a previous history of fractures.


IBD is associated with bone loss, and patients are at increased risk of developing fractures. Many risk factors are associated with reductions in BMD in this population, including inflammation, smoking, body composition, glucocorticoid use, vitamin D deficiency and surgery. Infliximab seems to increase BMD, but the exact mechanism is not well established. More studies are needed to analyze the effect of other anti-TNF therapies in BMD.


P- Reviewer: Chow WK, Rajendran VM S- Editor: Tian YL L- Editor: A E- Editor: Liu SQ

1.  Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585-595.  [PubMed]  [DOI]
2.  Miheller P, Gesztes W, Lakatos PL. Manipulating bone disease in inflammatory bowel disease patients. Ann Gastroenterol. 2013;26:296-303.  [PubMed]  [DOI]
3.  Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819-4831.  [PubMed]  [DOI]
4.  Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122:599-604.  [PubMed]  [DOI]
5.  Ng SC. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol. 2014;28:363-372.  [PubMed]  [DOI]
6.  Tsai MS, Lin CL, Tu YK, Lee PH, Kao CH. Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: a nationwide population-based cohort study. Int J Clin Pract. 2015;69:235-241.  [PubMed]  [DOI]
7.  Pinto Neto AM, Soares A, Urbanetz AA, Souza ACA, Ferrari AEM, Amaral B, Moreira C, Fernandes CE, Zerbini CAF, Baracat E. Brasilian Consensus on osteoporosis 2002. Rev Bras Reumatol. 2002;42:343-354.  [PubMed]  [DOI]
8.  American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases.  Gastroenterology. 2003;124:791-794.  [PubMed]  [DOI]
9.  Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841.  [PubMed]  [DOI]
10.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.  [PubMed]  [DOI]
11.  Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut. 2000;46 Suppl 1:i1-i8.  [PubMed]  [DOI]
12.  Targownik LE, Bernstein CN, Leslie WD. Inflammatory bowel disease and the risk of osteoporosis and fracture. Maturitas. 2013;76:315-319.  [PubMed]  [DOI]
13.  Miheller P, Lorinczy K, Lakatos PL. Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol. 2010;16:5536-5542.  [PubMed]  [DOI]
14.  Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133:795-799.  [PubMed]  [DOI]
15.  Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004;53:251-255.  [PubMed]  [DOI]
16.  van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:1591-1597.  [PubMed]  [DOI]
17.  Hilmi I, Sunderesvaran K, Ananda V, Sarji SA, Arumugam K, Goh KL. Increased fracture risk and osteoporosis not associated with vitamin D levels in Malaysian patients with inflammatory bowel disease. J Clin Endocrinol Metab. 2013;98:2415-2421.  [PubMed]  [DOI]
18.  Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313-319.  [PubMed]  [DOI]
19.  Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis. J Intern Med. 2000;247:63-70.  [PubMed]  [DOI]
20.  Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn’s disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol. 1999;94:824-828.  [PubMed]  [DOI]
21.  Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003;15:857-864.  [PubMed]  [DOI]
22.  Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrügger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203-1208.  [PubMed]  [DOI]
23.  Sakellariou GT, Moschos J, Berberidis C, Mpoumponaris A, Kadis S, Molyvas E, Kouklakis G. Bone density in young males with recently diagnosed inflammatory bowel disease. Joint Bone Spine. 2006;73:725-728.  [PubMed]  [DOI]
24.  Reinshagen M. Osteoporosis in inflammatory bowel disease. J Crohns Colitis. 2008;2:202-207.  [PubMed]  [DOI]
25.  Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473:139-146.  [PubMed]  [DOI]
26.  Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490-495.  [PubMed]  [DOI]
27.  Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57:684-694.  [PubMed]  [DOI]
28.  Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010;11:219-227.  [PubMed]  [DOI]
29.  Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev. 2005;208:207-227.  [PubMed]  [DOI]
30.  Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65:S147-S151.  [PubMed]  [DOI]
31.  Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012;11:234-250.  [PubMed]  [DOI]
32.  Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn’s disease. Eur J Gastroenterol Hepatol. 2009;21:159-166.  [PubMed]  [DOI]
33.  Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15:1267-1273.  [PubMed]  [DOI]
34.  Wong PK, Christie JJ, Wark JD. The effects of smoking on bone health. Clin Sci (Lond). 2007;113:233-241.  [PubMed]  [DOI]
35.  Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporos Int. 2012;23:2081-2092.  [PubMed]  [DOI]
36.  Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int. 2001;68:259-270.  [PubMed]  [DOI]
37.  Zali M, Bahari A, Firouzi F, Daryani NE, Aghazadeh R, Emam MM, Rezaie A, Shalmani HM, Naderi N, Maleki B. Bone mineral density in Iranian patients with inflammatory bowel disease. Int J Colorectal Dis. 2006;21:758-766.  [PubMed]  [DOI]
38.  Silvennoinen JA, Lehtola JK, Niemelä SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol. 1996;31:367-371.  [PubMed]  [DOI]
39.  Cosnes J. Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis. 2010;28:411-417.  [PubMed]  [DOI]
40.  De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16:1330-1338.  [PubMed]  [DOI]
41.  Azzopardi N, Ellul P. Risk factors for osteoporosis in Crohn’s disease: infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis. 2013;19:1173-1178.  [PubMed]  [DOI]
42.  Noble CL, McCullough J, Ho W, Lees CW, Nimmo E, Drummond H, Bear S, Hannan J, Millar C, Ralston SH. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:588-596.  [PubMed]  [DOI]
43.  Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn‘s disease. Inflamm Bowel Dis. 2002;8:87-92.  [PubMed]  [DOI]
44.  Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13:259-265.  [PubMed]  [DOI]
45.  Atreja A, Aggarwal A, Licata AA, Lashner BA. Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. ScientificWorldJournal. 2012;2012:807438.  [PubMed]  [DOI]
46.  Leslie WD, Miller N, Rogala L, Bernstein CN. Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Inflamm Bowel Dis. 2009;15:39-46.  [PubMed]  [DOI]
47.  Cawsey S, Padwal R, Sharma AM, Wang X, Li S, Siminoski K. Women with severe obesity and relatively low bone mineral density have increased fracture risk. Osteoporos Int. 2015;26:103-111.  [PubMed]  [DOI]
48.  Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab. 2007;92:1640-1646.  [PubMed]  [DOI]
49.  Johansson H, Kanis JA, Odén A, McCloskey E, Chapurlat RD, Christiansen C, Cummings SR, Diez-Perez A, Eisman JA, Fujiwara S. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res. 2014;29:223-233.  [PubMed]  [DOI]
50.  Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn’s disease: exercise as a potential countermeasure. Inflamm Bowel Dis. 2005;11:1108-1118.  [PubMed]  [DOI]
51.  Turner CH, Robling AG. Exercise as an anabolic stimulus for bone. Curr Pharm Des. 2004;10:2629-2641.  [PubMed]  [DOI]
52.  Mauro M, Armstrong D. Evaluation of densitometric bone-muscle relationships in Crohn’s disease. Bone. 2007;40:1610-1614.  [PubMed]  [DOI]
53.  Lee N, Radford-Smith GL, Forwood M, Wong J, Taaffe DR. Body composition and muscle strength as predictors of bone mineral density in Crohn’s disease. J Bone Miner Metab. 2009;27:456-463.  [PubMed]  [DOI]
54.  Targownik LE, Bernstein CN, Leslie WD. Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol. 2014;30:168-174.  [PubMed]  [DOI]
55.  Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol. 2003;98:1797-1801.  [PubMed]  [DOI]
56.  Abraham BP, Prasad P, Malaty HM. Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. Dig Dis Sci. 2014;59:1878-1884.  [PubMed]  [DOI]
57.  Mitra R. Adverse effects of corticosteroids on bone metabolism: a review. PM R. 2011;3:466-471; quiz 471.  [PubMed]  [DOI]
58.  Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319-1328.  [PubMed]  [DOI]
59.  van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006;79:129-137.  [PubMed]  [DOI]
60.  Rodríguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol. 2007;13:6156-6165.  [PubMed]  [DOI]
61.  Garg M, Lubel JS, Sparrow MP, Holt SG, Gibson PR. Review article: vitamin D and inflammatory bowel disease--established concepts and future directions. Aliment Pharmacol Ther. 2012;36:324-344.  [PubMed]  [DOI]
62.  Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res. 2011;26:1609-1616.  [PubMed]  [DOI]
63.  Reich KM, Fedorak RN, Madsen K, Kroeker KI. Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. World J Gastroenterol. 2014;20:4934-4947.  [PubMed]  [DOI]
64.  Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;39:125-136.  [PubMed]  [DOI]
65.  Blanck S, Aberra F. Vitamin d deficiency is associated with ulcerative colitis disease activity. Dig Dis Sci. 2013;58:1698-1702.  [PubMed]  [DOI]
66.  Jørgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Dahlerup JF. Active Crohn’s disease is associated with low vitamin D levels. J Crohns Colitis. 2013;7:e407-e413.  [PubMed]  [DOI]
67.  Kawai VK, Stein CM, Perrien DS, Griffin MR. Effects of anti-tumor necrosis factor α agents on bone. Curr Opin Rheumatol. 2012;24:576-585.  [PubMed]  [DOI]
68.  Lee KS, Kim IY, Kim PN. Dissecting intramural hematoma of the esophagus in Boerhaave syndrome: CT findings. AJR Am J Roentgenol. 1991;157:197-198.  [PubMed]  [DOI]
69.  Miheller P, Muzes G, Rácz K, Blázovits A, Lakatos P, Herszényi L, Tulassay Z. Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm Bowel Dis. 2007;13:1379-1384.  [PubMed]  [DOI]
70.  Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006;40:55-63.  [PubMed]  [DOI]
71.  Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P. Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2004;20:607-614.  [PubMed]  [DOI]
72.  Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn’s disease patients. Can J Gastroenterol. 2007;21:637-642.  [PubMed]  [DOI]
73.  Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn‘s disease. Ann N Y Acad Sci. 2006;1068:543-556.  [PubMed]  [DOI]
74.  Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, Cimaz R, Cimino L, Gionchetti P, Girolomoni G. Adalimumab in the treatment of immune-mediated diseases. Int J Immunopathol Pharmacol. 2014;27:33-48.  [PubMed]  [DOI]
75.  Durnez A, Paternotte S, Fechtenbaum J, Landewé RB, Dougados M, Roux C, Briot K. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study. J Rheumatol. 2013;40:1712-1718.  [PubMed]  [DOI]
76.  Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68:373-376.  [PubMed]  [DOI]
77.  Krieckaert CL, Nurmohamed MT, Wolbink G, Lems WF. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford). 2013;52:547-553.  [PubMed]  [DOI]
78.  Shen B, Remzi FH, Oikonomou IK, Lu H, Lashner BA, Hammel JP, Skugor M, Bennett AE, Brzezinski A, Queener E. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol. 2009;104:639-646.  [PubMed]  [DOI]
79.  Gupta S, Shen B. Bone loss in patients with the ileostomy and ileal pouch for inflammatory bowel disease. Gastroenterol Rep (Oxf). 2013;1:159-165.  [PubMed]  [DOI]
80.  Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, Schroeder TK. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120-127.  [PubMed]  [DOI]
81.  Navaneethan U, Shen L, Venkatesh PG, Hammel J, Patel V, Remzi FH, Kiran RP. Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients. J Crohns Colitis. 2011;5:415-422.  [PubMed]  [DOI]
82.  Gupta S, Wu X, Moore T, Shen B. Frequency, risk factors, and adverse sequelae of bone loss in patients with ostomy for inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:259-264.  [PubMed]  [DOI]